PT - JOURNAL ARTICLE AU - Harris, Hannah M. AU - Boyet, Katherine L. AU - Liu, Hao AU - Dwivedi, Rohini AU - Ashpole, Nicole M. AU - Tandon, Ritesh AU - Bidwell, Gene L. AU - Pomin, Vitor H. AU - Mitra, Dipanwita AU - Harrison, Kerri A. AU - Dahl, Eric AU - Gurley, Bill J. AU - Kotha, Arun Kumar AU - Chougule, Mahavir Bhupal AU - Sharp, Joshua S. TI - Safety and Pharmacokinetics of Intranasally Administered Heparin AID - 10.1101/2021.07.05.21259936 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.05.21259936 4099 - http://medrxiv.org/content/early/2021/07/06/2021.07.05.21259936.short 4100 - http://medrxiv.org/content/early/2021/07/06/2021.07.05.21259936.full AB - Purpose Intranasally administered unfractionated heparin (UFH) and other sulfated polysaccharides are potential prophylactics for COVID-19. The purpose of this research was to measure the safety and pharmacokinetics of clearance of intranasally administered UFH solution from the nasal cavity.Methods Double-blinded daily intranasal dosing in C57Bl6 mice with four doses (60 ng to 60 µg) of UFH was carried out for fourteen consecutive days, with both blood coagulation measurements and subject adverse event monitoring. The pharmacokinetics of fluorescent-labeled UFH clearance from the nasal cavity were measured in mice by in vivo imaging. Intranasal UFH at 2000 U/day solution with nasal spray device was tested for safety in a small number of healthy human subjects.Results UFH showed no evidence of toxicity in mice at any dose measured. No significant changes were observed in activated partial thromboplastin time (aPTT), platelet count, or frequency of minor irritant events over vehicle-only control. Human subjects showed no significant changes in aPTT time, international normalized ratio (INR), or platelet count over baseline measurements. No serious adverse events were observed. In vivo imaging in a mouse model showed a two-phase clearance of UFH from the nasal cavity. After 12 hours, 2.1% of the initial administered UFH remained in the nasal cavity, decaying to background levels after 24 hours.Conclusions UFH showed no toxic effects for extended daily intranasal dosing in mice as well as humans. The clearance kinetics of intranasal heparin solution from the nasal cavity indicates potentially protective levels for up to 12 hours after dosing.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04490239Funding StatementThis work was supported in part by the University of Mississippi and the NIH funded Neuropharmacology Core Facility (P30 GM122733). The authors are thankful to Dr. Ward Brister, Brister's H & W Compounding Pharmacy, Grenada, MS for providing the U line nasal spray bottle with pump.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Mississippi Institutional Research Board Protocol #19-009 (mouse toxicology) University of Mississippi Medical Center Institutional Animal Care and Use Committee Protocol #1571 (mouse pharmacokinetics) University of Mississippi Institutional Research Board Protocol #21-004 (healthy human subject trial)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.